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Abstract
Dysglycaemic disease is one of the most important health issues facing the world in the 21st century.
Patients with type 2 diabetes and individuals with prediabetes are at risk of developing
macrovascular and microvascular complications. Long-term management strategies are therefore
required that are effective at controlling dysglycaemia, well tolerated and, ideally, offer additional
cardiovascular disease (CVD) risk-reduction benefits. The efficacy, safety and tolerability of the α-
glucosidase inhibitor acarbose have been well-established in a wide range of patient populations in
both clinical and community trials. In addition, acarbose has been shown to reduce cardiovascular
complications in type 2 diabetes and prevent hypertension and CVD in individuals with impaired
glucose tolerance (IGT). Acarbose has a very good safety profile and, owing to its straightforward,
non-systemic mode of action, avoids most adverse events. The most common side-effects of
acarbose are mild-to-moderate gastrointestinal complaints that subside as treatment continues.
They can be minimised through the use of an appropriate stepwise dosing regimen and careful
choice of diet. Acarbose is therefore a valuable option for the management of type 2 diabetes and,
as the only oral antidiabetes agent approved for the treatment of prediabetes, can help to improve
clinical management across the dysglycaemic disease continuum.
Background
Cardiovascular disease (CVD) is the leading cause of mor-
tality associated with dysglycaemia. Type 2 diabetes
accounts for almost one in ten of all deaths around the
world each year, and up to 80% of these deaths are CVD-
related [1,2]. Moreover, there is now substantial evidence
to show that the prediabetic state of impaired glucose tol-
erance (IGT) is itself a significant CVD risk factor [3,4].
Several management strategies have been proposed for
the early stages of dysglycaemia, with the aim of prevent-
ing the development of type 2 diabetes and associated
complications, such as CVD. A key strategy is "lifestyle
modification", involving changes in diet and exercise,
which was shown in both the US Diabetes Prevention
Program (DPP) and the Finnish Diabetes Prevention
Study (DPS) to reduce the incidence of type 2 diabetes by
58% [5,6]. However, although lifestyle modification is a
vital part of dysglycaemia management, it is often insuffi-
cient to maintain long-term glycaemic control. In such
cases, pharmacological intervention will be required; such
treatment should place the minimum additional strain on
a patient's metabolic, endocrine and vascular systems.
Consequently, several antidiabetes and other medications
have been studied to determine their potential benefits in
the prevention of type 2 diabetes.
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Results from trials of acarbose, metformin and rosiglita-
zone in prediabetic populations are summarised in Table
1. The Study to Prevent Non-Insulin Dependent Diabetes
Mellitus (STOP-NIDDM) found that treatment with acar-
bose reduces the incidence of type 2 diabetes by 36% [7].
In the DPP, treatment with metformin reduced the inci-
dence of diabetes by 31%, although this effect was less
marked in older patients, perhaps owing to age-related
differences in insulin secretion [5,8]. The DPP also found
a significant reduction in the incidence of diabetes with
troglitazone, another insulin sensitiser; however, troglita-
zone was discontinued before the end of the study owing
to concerns regarding liver toxicity [9]. More recently, the
structurally related drug rosiglitazone was found to reduce
the risk of type 2 diabetes and increase reversion to nor-
mal glucose tolerance when administered in addition to
lifestyle modification [10]. Although no liver toxicity was
observed in this study, patients receiving rosiglitazone did
have a significantly increased risk of chronic heart failure
(p = 0.01) [11].
Some cardiovascular drugs have also shown potential
antidiabetes effects. Bezafibrate, which lowers triglyceride
levels and raises high-density lipoprotein (HDL)-choles-
terol levels, has been shown to delay the onset of type 2
diabetes in obsese patients and patients with IGT [12,13].
A recent meta-analysis concluded that the use of renin-
angiotensin system antagonists (angiotensin-converting
enzyme [ACE] inhibitors or angiotensin receptor blockers
[ARBs]) may contribute to the prevention of type 2 diabe-
tes [14]. Equally, a number of recent trials have focussed
on the potential of oral antidiabetes drugs to reduce cardi-
ovascular risk, although in most cases further research is
needed [15].
Increasing evidence supports the benefits of early treat-
ment with α-glucosidase inhibitors such as acarbose.
These agents directly target postprandial hyperglycaemia,
which has been identified as an important cardiovascular
risk factor in its own right [16,17]. As a result of their non-
systemic mode of action – they are active in the gut and
not absorbed into the body – α-glucosidase inhibitors are
considered to be one of the safest and best-tolerated
classes of antidiabetes agents available [18].
The efficacy of acarbose has been confirmed in more than
350 studies involving more than 30,000 patients [19].
Acarbose has been shown to be as efficacious as other
commonly used antidiabetes agents, and to have an excel-
lent safety profile with minimal drug-drug interactions. It
has been proven to reduce the incidence of type 2 diabetes
and hypertension in people with IGT [7,20]; in addition,
studies in both prediabetes and type 2 diabetes popula-
tions have demonstrated that the use of acarbose is asso-
ciated with reductions in cardiovascular events [20,21]
and with beneficial effects on a broad spectrum of CV risk
factors. Acarbose is currently the only oral antidiabetes
agent approved for the treatment of both prediabetes and
type 2 diabetes.
Direct targeting of postprandial hyperglycaemia
Postprandial hyperglycaemia is known to contribute to
the development of endothelial dysfunction [22,23], and
to increase the risk of cardiovascular and all-cause mortal-
ity, even before diabetes is diagnosed [17,24,25]. Hyperg-
lycaemia is also one of the metabolic abnormalities that
defines metabolic syndrome [25,26]. Patients with predi-
abetes and type 2 diabetes are therefore more likely than
the general population to develop dyslipidaemia and
hypertension. The International Diabetes Federation
(IDF) has estimated that approximately 500 million peo-
ple worldwide suffer from some degree of dysglycaemia
[27,28]. To meet the healthcare challenges posed by this
epidemic, diabetologists and primary care physicians
need to be aware of the most appropriate treatment
options for all stages of the disease continuum.
Acarbose binds with high affinity and specificity to α-glu-
cosidases found in the brush border of the small intestine.
Under normal circumstances, these enzymes are responsi-
ble for the hydrolysis of complex carbohydrates (starch
and other oligosaccharides) to absorbable simple sugars
(monosaccharides, most importantly glucose). Alpha-glu-
cosidases are found along the length of the intestine, but
Table 1: Use of oral antidiabetes drugs to treat individuals with prediabetes: effect on cardiovascular and diabetes outcomes.
Study DREAM [94] (Rosiglitazone) STOP-NIDDM [7,20] (Acarbose) DPP [5,48]
Patient population IGT/IFG n = 5269 IGT n = 1368 IGT n = 2155
Effect of intervention on diabetes 
incidence
-60% (p < 0.0001) -36.4% (p = 0.003) -31% (p < 0.01)
Effect of intervention on new 
hypertension incidence
n/a -34% (p = 0.006) +25% (not significant)
Effect of intervention on rate of 
predefined CV events
+37% (p = 0.08) -49% (p = 0.03) n/a
DREAM: Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication. STOP-NIDDM: Study to Prevent Non-Insulin Dependent 
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in Western populations current dietary habits typically
mean that in most people they are only active in the upper
small intestine. The effect of acarbose is to delay the diges-
tion of oligosaccharides in the small intestine so that the
release and absorption of glucose takes place over a longer
time across the length of the small intestine (Figure 1)
[29]. The result is that acarbose therapy directly reduces
postprandial hyperglycaemia [30]. A Cochrane review of
30 acarbose monotherapy trials, which included more
than 5,000 patients with type 2 diabetes, demonstrated
that acarbose treatment reduces 1-hour postload plasma
glucose levels by 2.3 mmol/L with a clear dose-response
relationship, as well as fasting plasma glucose (FPG) lev-
els and HbA1c levels – a measure of long-term glycaemic
control [31].
In 24-week face-to-face comparison trials, similar reduc-
tions in the level of glycated haemoglobin (HbA1c) were
seen for acarbose and metformin (1.1% and 1.0%, respec-
tively) [32], and for acarbose and glibenclamide (1.1%
and 0.9%, respectively) [33]. The Cochrane review  also
found that acarbose is at least as effective at controlling
postprandial hyperglycaemia as commonly used oral anti-
diabetics,  short-acting insulin secretagogues and the long-
acting sulphonylurea  glibenclamid  [31]. The natural pro-
gression of diabetes involves increasing insulin resistance
and loss of pancreatic β-cell function, and antidiabetes
therapies that trigger insulin secretion therefore fail over
time. The mechanism of action of acarbose, however, lim-
its the burden on β-cells, and studies have shown that the
effectiveness of acarbose is maintained in long-term treat-
ment, with no secondary failure. A 5-year surveillance
study of patients with diabetes found that acarbose
reduced 2-hour postprandial blood glucose (2 hPG) levels
by 3.4 mmol/L and HbA1c levels by 1.8% from baseline
[18,34]. By contrast, the effectiveness of some other oral
antidiabetic drugs, such as glibenclamide, is dependent
on adequate β-cell function, and is therefore likely to
decline as diabetes progresses, as shown in the UKPDS
[35] and other studies [18,36].
Preventing cardiovascular disease with acarbose
The link between dysglycemia – and postprandial hyperg-
lycaemia in particular – and cardiovascular risk is well
established [17,37-39]. Type 2 diabetes, for instance, is a
reliable independent predictor of mortality after a myo-
cardial infarction (MI), [40] and blood glucose levels have
been shown to be a continuous risk factor for CVD mor-
tality even below the diabetic threshold [41,42].
The cardiovascular benefits of acarbose in individuals
with IGT were shown by STOP-NIDDM. The study found
that the reduction in postprandial hyperglycaemia with
acarbose therapy was not only associated with a 36%
reduction in newly diagnosed diabetes, but also with a
34% relative risk reduction in the incidence of new cases
of hypertension (P = 0.006) and a 49% relative risk reduc-
tion in the development of cardiovascular events (P  =
0.03) over a mean follow-up of 3.3 years (Table 1) [20].
Moreover, the risk of MI specifically was reduced by 91%
(P = 0.02), a result that remained significant even when an
additional eight silent MIs were identified and included in
the analysis (total of two clinically overt and silent MIs in
the acarbose group, compared with 19 in the placebo
group; P = 0.001)[43].
Other oral antidiabetes agents used for the prevention of
diabetes in patients with IGT have not been shown to pro-
duce similar reductions in CVD risk. In the recent DREAM
(Diabetes REduction AssessMent with ramipril and rosigl-
itazone) study, the effect of treatment with the thiazolid-
Acarbose delays the absorption of carbohydrates from the  gut Figure 1
Acarbose delays the absorption of carbohydrates from the 
gut.
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inedione rosiglitazone on the incidence of cardiovascular
events in prediabetic individuals was assessed as a second-
ary endpoint. The composite cardiovascular endpoint was
not significantly different between the two groups (hazard
ratio [HR], 1.37; 95% confidence interval [CI], 0.97–1.94;
P = 0.08)[44]. However, despite the fact that the study was
carried out in a population at low risk for cardiovascular
events, significantly more participants developed conges-
tive heart failure in the rosiglitazone group than in the
placebo group (14 vs 2 participants, respectively; HR,
7.03; 95% CI, 1.60–30.9; P = 0.01)[45]. The MEta-analy-
sis of Risk Improvement under Acarbose (MeRIA), which
analysed the results of seven long-term trials carried out in
patients with type 2 diabetes, confirmed that treatment
with acarbose has broader benefits for the management of
vascular disease and damage [21]. The primary endpoint
of the MeRIA analysis was the time to develop a cardiovas-
cular event. Treatment with acarbose reduced the risk of
any cardiovascular event by 35% (P = 0.0061), and the
risk of MI specifically by 64% (P = 0.0120; Figure 2) [21].
Trends towards risk reduction were observed for all other
selected cardiovascular events, including angina, heart
failure and stroke.
The effects of a thiazolidinedione, pioglitazone, on the
secondary prevention of cardiovascular events in patients
with type 2 diabetes was assessed in PROactive (PROspec-
tive pioglitAzone Clinical Trial In macrovascular eVEnts);
this study also failed to show a significant reduction in the
primary CV endpoint with treatment [46]. In the UKPDS,
metformin was shown to reduce the incidence of myocar-
dial infarction (P = 0.010) and all-cause mortality (P =
0.011) in obese type 2 diabetes patients [47]. However, in
the Diabetes Prevention Programme, which randomised
3,234 individuals with IGT to intensive lifestyle modifica-
tion, metformin or placebo, there was no difference in the
incidence of cardiovascular events between the treatment
groups over 3 years [48].
Improvements in cardiovascular risk factors with acarbose
The rapid rise in postprandial blood glucose levels associ-
ated with IGT damages the endothelium of the arterial
wall and initiates a cascade of pro-atherogenic events (Fig-
ure 3) [23,49]. Research is ongoing to determine the
mechanisms by which acarbose provides cardiovascular
benefits, but it seems clear that the benefits can be attrib-
uted, at least in part, to the fact that acarbose directly tar-
gets postprandial hyperglycaemia, which limits
endothelial damage and reduces the risk of macrovascular
complications. For example, a substudy of STOP-NIDDM
found that acarbose slows the progression of intima-
media thickening (IMT) in individuals with prediabetes;
compared with placebo, acarbose treatment reduced the
annual increase in carotid IMT by approximately 50% (P
= 0.027)[22]. This result is supported by the results of a
subsequent study in which acarbose treatment was shown
to preserve endothelial vasodilation compared with pla-
cebo [23].
Patients with type 2 diabetes are at high risk for the other
components of metabolic syndrome, including dyslipi-
daemia and hypertension, which have been shown to lead
to increased morbidity and mortality [26,50]. It has been
suggested that management of metabolic syndrome
should focus on the prevention of diabetes and CVD [51],
and treatment with acarbose has been shown to have ben-
efits for several metabolic syndrome components.
For example, in contrast to other oral antidiabetes agents,
acarbose is not associated with weight gain. The use of
sulphonylureas, glinides or thiazolidinediones to manage
type 2 diabetes is associated with a typical weight gain of
2–5 kg [52], but a randomised controlled comparison of
acarbose and glibenclamide as monotherapy in 96
patients with diabetes found no weight changes associ-
ated with acarbose therapy [32]. Moreover, a 22-week trial
found that acarbose therapy caused a significant reduction
in weight compared with placebo (P < 0.01)[53], a result
confirmed by the MeRIA analysis [21]. Nor does acarbose
therapy lead to weight gain in patients with prediabetes:
in STOP-NIDDM, after 3.2 years, individuals receiving
acarbose had lost a mean of 1.2 kg, compared with indi-
viduals receiving placebo [7]. These benefits cannot be
explained by changes in dietary habits [54,55].
Between 20% and 60% of patients with type 2 diabetes
will develop hypertension [56]. A double-blind, ran-
domised, placebo-controlled study in 44 patients with
type 2 diabetes found that achievement of good glycaemic
Acarbose reduces the risk of myocardial infarction in  patients with type 2 diabetes Figure 2
Acarbose reduces the risk of myocardial infarction in 
patients with type 2 diabetes. [21]
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control with acarbose was accompanied by significant
reductions in diurnal systolic, diastolic and mean blood-
pressure values (P < 0.05)[53]. Similarly, a randomised 6-
month study in obese patients with diabetes found that
acarbose treatment reduced the mean 24-hour systolic
blood pressure by a mean of 5.2 mmHg, compared with
only 1.6 mmHg with glibenclamide (P = 0.0001, Figure 4)
[57]. Again, these results were confirmed by the MeRIA
analysis, which found that acarbose treatment signifi-
cantly reduces systolic blood pressure (P = 0.024)[21,58].
Reductions in postprandial hyperglycaemia in patients
with type 2 diabetes as a result of treatment with acarbose
have also been shown to reduce the activity (P = 0.045)
and nuclear localisation (P = 0.02) of the proinflamma-
tory transcription factor NFκB [59], suggesting a mecha-
nism by which the anti-inflammatory effects of acarbose
may be mediated. This mechanism would be consistent
with reductions in the levels of coagulation factors seen
with acarbose treatment. For example, acarbose has been
shown to reduce the level of fibrinogen in patients with
type 2 diabetes (P = 0.013 vs placebo)[60], and to reduce
serum C-reactive protein levels in individuals with IGT (P
< 0.01 vs placebo)[61]. However, unlike acarbose, most
treatments for type 2 diabetes, such as metformin and
sulphonylureas, have a greater effect on FPG levels than
on postprandial hyperglycaemia [62], and may not lead to
cardiovascular benefits by these mechanisms. Further-
more, an analysis of 24-hour insulin and proinsulin pro-
files in type 2 diabetes patients treated with either
acarbose or glibenclamide found that acarbose signifi-
cantly reduced diurnal levels of proinsulin (P < 0.05)[63].
Improvement of insulin sensitivity by acarbose has been
shown with hyperglycaemic clamp measurements in eld-
erly patients with type 2 diabetes [64].
Side-effects and tolerability of acarbose
Numerous clinical and surveillance studies have con-
firmed that, in contrast to other antidiabetes medications,
in particular thiazolidinediones, acarbose treatment is
associated with very few serious side-effects. The 28-week
Precose Resolution of Optimal Titration to Enhance Cur-
rent Therapies (PROTECT) trial, which followed more
than 6,000 patients with type 2 diabetes in a real-world
setting, concluded that acarbose has an excellent safety
profile irrespective of patients' age, weight, ethnicity, the
time since their diagnosis and the presence or absence of
concomitant therapy [65].
The most common side-effects seen with acarbose are
mild-to-moderate gastrointestinal (GI) side-effects,
including flatulence, diarrhoea and abdominal disten-
sion. In phase 3 trials in the USA, 56–76% of patients
receiving acarbose reported side-effects, of which almost
all were GI-related. However, side-effects were also
reported by 32–37% of patients receiving placebo
[18,66]. In addition, a 24-week study of 495 patients with
diabetes from seven European countries found that, of
patients who received acarbose and reported flatulence
during the first 2 weeks of therapy, only about half
reported flatulence during the last 4 weeks [18,67]. Most
GI sideeffects, therefore, become less common as therapy
continues [18,66]. A 12-week postmarketing surveillance
study of 27,803 patients with diabetes found that 13.7%
reported flatulence and 2.2% reported diarrhoea; 83% of
patients reported no adverse reactions [18,68]. Further-
more, a 5-year surveillance study of 1,954 patients with
diabetes found that GI side-effects associated with acar-
bose were reported by only 3.9% of patients (Table
2)[18,69].
Table 2: Safety profile of acarbose, 5-year surveillance study (n = 
1,954) [34].
Side-effect n Proportion of 
total 
population (%)
Gastrointestinal 76 3.9
Flatulence 68 3.5
Diarrhoea 13 0.7
Loose stool 1 <0.1
Abdominal 4 0.2
Nausea 3 0.2
Constipation 1 <0.1
Metabolic 10 0.5
Body as a whole 5 0.3
The role of postprandial hyperglycaemia in the development  of type 2 diabetes and CVD Figure 3
The role of postprandial hyperglycaemia in the development 
of type 2 diabetes and CVD.
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The GI side-effect profile of acarbose is linked to the drug's
mechanism of action. In many individuals, α-glucosi-
dases are most active in the upper small intestine. As a
result, in the early stages of therapy, some undigested car-
bohydrate reaches the colon. There, it undergoes fermen-
tation by colonic bacteria, resulting in the formation of
fatty acids, which are absorbed by the body, and gaseous
byproducts, which cause GI side-effects. As acarbose treat-
ment continues, there is a compensatory increase in
enzyme activity in the lower small intestine [18,69]. Fur-
thermore, exposure of the lower small intestine to undi-
gested carbohydrate leads to an increased quantity and
duration of glucagon-like peptide-1 (GLP-1) release [70].
These adaptations explain the reduction in GI side-effects
over time.
Patient compliance with pharmacological therapy is
affected by both the efficacy and tolerability of the drugs
taken. A double-blind, placebo-controlled substudy of
acarbose in 1,946 patients was initiated 4 years before the
end of the UKPDS; it found that most discontinuations
from acarbose therapy occurred during the first year of
treatment [71], and in the 5-year open-label surveillance
study, two-thirds of side-effects were reported in the first
3 months [34]. In STOP-NIDDM, which recruited 1,429
individuals with IGT, 48% of those who discontinued
early did so in the first year, and the most common single
cause of discontinuation was GI side-effects [7]. Trial
results indicate that initial intolerance owing to GI side-
effects is transient, and that once tolerance is achieved,
compliance is easier to maintain. In addition, owing to its
mechanism of action, the effectiveness of acarbose does
not decrease over time.
The side-effect profiles of two different acarbose dosing
regimens, compared with placebo, were determined in a
multicentre trial of 164 outpatients with type 2 diabetes
[72]. A stepwise-increasing regimen, in which acarbose
therapy was initiated at 50 mg twice daily and progressed
to 100 mg three-times daily, was found to be as effective
at reducing postprandial glucose levels as a flat-dosing
regimen, in which patients received 100 mg three-times
daily from the outset. Both regimens significantly reduced
2 hPG and mean HbA1c levels (both P < 0.0001 vs pla-
cebo). However, the stepwise-dosing regimen was associ-
ated with significantly fewer GI side-effects (Figure 5, P <
0.05) that were significantly less persistent than the flat-
dosing regimen over the course of treatment. The mean
duration of GI side-effects for patients in the stepwise-dos-
ing group was 29 days, compared with 21 days in the pla-
cebo group and 42 days in the flat-dosing group (P <
0.05)[72]. A 'start low, go slow' stepwise-dosing regimen
is, therefore, recommended to minimise side-effects
[73,74]. To minimise the disruptive effects of any GI side-
effects, depending on regional dietary habits, some physi-
cians recommend that when initiating acarbose it may be
more effective to take the initial once-daily dose with the
evening meal, rather than with breakfast [75].
In STOP-NIDDM, administration of acarbose was initi-
ated at 50 mg/day and titrated by 50 mg/day every 2 weeks
to a maximum of 100 mg three-times daily (or the maxi-
mum tolerated dose)[76]. The same regimen was used in
the UKPDS [71] and a similar regimen was used in a Chi-
nese study [77], whereas in the PROTECT trial acarbose
was titrated from 25 mg three-times daily to 50 mg three-
times daily, and finally to 100 mg three-times daily based
on efficacy and tolerability [65]. In all these trials, acar-
bose was shown to effectively reduce hyperglycaemia, and
in STOP-NIDDM, acarbose also significantly increased
reversion of IGT to normal glucose tolerance (P  <
0.0001)[7]. Furthermore, these trials demonstrated that
the full maximum dose (300 mg three-times daily) is not
required in all patients. The mean daily dose in STOP-
NIDDM was 194 mg [7], compared with 201 mg in the 5-
year surveillance study [34]. The low prevalence of side-
effects in the surveillance study may be explained by the
physician tailoring the dose of acarbose to the individual
patient in a community setting [34].
Other factors can also impact on the effectiveness of acar-
bose treatment, and therefore potentially affect compli-
ance. Enzyme activity in the gut varies among individuals
and among populations, and can lead to variations in the
initial response to acarbose treatment [75]. In addition,
because the effects of acarbose are the result of competi-
tive inhibition, acarbose must be present at the active site
of its target enzymes at the same time as the ingested car-
bohydrates. Maximal effectiveness is therefore achieved if
Mean systolic and diastolic blood pressure in patients with  hypertension and type 2 diabetes treated with acarbose or  glibenclamide for 6 months Figure 4
Mean systolic and diastolic blood pressure in patients with 
hypertension and type 2 diabetes treated with acarbose or 
glibenclamide for 6 months. Adapted with permission from 
Rosenthal & Mausersberger. [57]Cardiovascular Diabetology 2007, 6:20 http://www.cardiab.com/content/6/1/20
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acarbose is given within 15 minutes of the start of a meal,
and it is recommended that acarbose is taken with the first
bite of a meal [78].
The carbohydrate composition of a meal can also affect
the efficacy and tolerability of acarbose therapy. A diet
high in complex carbohydrates and low in simple sugars
is recommended for most patients with diabetes, but is
particularly important for patients receiving acarbose
[79]. A very high intake of simple sugars may aggravate GI
side-effects, because they may be present in too high a
concentration to be absorbed in the upper small intestine.
Therefore, if side-effects are reported, dietary management
will help to overcome them. Physicians and nurses should
explain that GI symptoms are part of the mode of action
of acarbose, and usually disappear with continuous treat-
ment.
Safety profile of acarbose
The mechanism of action of acarbose, and its unique,
non-systemic pharmacology, avoids several common
adverse events associated with other antidiabetes thera-
pies, and consequently, acarbose has few contraindica-
tions [18,66]. For example, hypoglycaemia, which is
caused by an excess of insulin, is a limiting factor in near-
to-normal control of hyperglycaemia [80,81], and is a sig-
nificant cause of morbidity and mortality [82]. Due to its
mode of action, acarbose does not stimulate insulin secre-
tion, and therefore monotherapy is not expected to cause
hypoglycaemia [81]. The UKPDS found that there was no
difference between acarbose and placebo for the risk of
major or minor hypoglycaemic episodes [71]. By contrast,
the use of insulin secretagogues (sulphonylureas and gli-
nides) is associated with an increased risk of hypoglycae-
mia [52]. In the UKPDS, the incidence of any
hypoglycaemic episode with sulphonylurea therapy was
17.7% [83]; in general, the incidence of severe hypogly-
caemia with this therapy class is estimated to be 1–2% per
year [52].
Acarbose is poorly absorbed into the bloodstream, and
has a low systemic availability of less than 2% [84]. As a
result, the risk of any toxic reaction is very low and, to
date, no interactions have been reported between acar-
bose and β-blockers, sulphonylureas, angiotensin-con-
verting enzyme (ACE) inhibitors or warfarin therapy [18].
Some other antidiabetes agents are contraindicated with
other treatments; for example, concomitant use of repagli-
nide with gemfibrozil, a lipid-lowering agent that acts by
inhibiting cytochromes, can cause prolonged hypoglycae-
mia [52].
Acarbose has been associated with rare cases of hepatotox-
icity [85] and increased liver enzyme levels [66], but these
have not been confirmed in major trials. A few cases of ful-
minant hepatitis with fatal outcome have been reported
[86,87]; but a causal relationship with acarbose treatment
has not been clearly established [85]. A trial of 20 patients
with diabetes and either chronic hepatitis or liver cirrhosis
found that acarbose significantly decreased the level of
HbA1c, from 7.2% at entry to 6.3% (P < 0.05) after 8 weeks
[88]. More recently, a larger trial of 107 cirrhotic patients
with diabetes found that, over 8 weeks, acarbose reduced
postprandial glucose levels by about 50%, with no
changes in liver function [89]. By contrast, sulphonylu-
reas, metformin and some thiazolidinediones are con-
traindicated in patients with moderate-to-severe liver
dysfunction [52,65].
Diabetes and many diabetic complications are particu-
larly common in elderly individuals [90]. Acarbose has
been safely used in elderly patients. A randomised con-
trolled trial of 192 patients with type 2 diabetes aged ≥ 65
years found that acarbose monotherapy controlled blood-
glucose levels, with no cases of hypoglycaemia reported
and no clinically relevant changes in vital signs during the
study [91]. A large postmarketing surveillance study con-
firmed that acarbose is effective at controlling blood-glu-
cose levels in elderly patients, and also found that the
incidence of adverse events with acarbose was low and
independent of age [68]. Clinical observations also show
that elderly patients receiving acarbose report fewer prob-
lems with constipation.
Diabetes accounts for 44% of new cases of end-stage renal
disease, making it a leading cause of nephropathy [92].
However, there are few data available regarding the use of
acarbose in patients with renal disease. Current recom-
Numbers of patients with intestinal side-effects receiving pla- cebo (n = 55), 100 mg acarbose (n = 54), and 100 mg acar- bose with stepwise dosing (n = 55) during 12-week  treatment Figure 5
Numbers of patients with intestinal side-effects receiving pla-
cebo (n = 55), 100 mg acarbose (n = 54), and 100 mg acar-
bose with stepwise dosing (n = 55) during 12-week 
treatment. Adapted with permission from May. [72]
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mendations therefore state that acarbose should not be
given to patients with severe renal impairment. A number
of other therapies are contraindicated in this patient pop-
ulation; for example, the use of metformin in patients
with renal impairment is associated with an increased risk
of lactic acidosis, which can be fatal [36].
The long-term safety of acarbose has been demonstrated
in placebo-controlled trials and in postmarketing surveil-
lance studies. In the randomised, double-blind UKPDS,
patients visited hospital-based clinics at 4-month inter-
vals. Acarbose, in combination with other antidiabetes
therapies, maintained a good safety profile over 3 years
[71]. A 2-year, more-closely monitored trial in 74 patients
with diabetes reported a similar level of adverse events as
the UKPDS, and no serious adverse events were consid-
ered to be related to acarbose [93]. Safety in an IGT popu-
lation was demonstrated by STOP-NIDDM, over a mean
follow-up of 3.2 years [7]. By extrapolation – and in con-
trast to treatment with metformin or thiazolidine – no
laboratory safety monitoring is required when treatment
with acarbose is initiated.
Conclusion
Numerous trials have demonstrated that acarbose is a safe
and effective oral antidiabetes agent in patients with dia-
betes and individuals with IGT. These findings have been
confirmed in a wide range of patient populations and in
long-term studies. The effect of acarbose on the incidence
of type 2 diabetes is comparable to that of metformin, and
in addition, acarbose is the only OAD that has been
shown to reduce the risk of prespecified cardiovascular
events irrespective of individuals' age and weight. Acar-
bose has been shown to improve hypertension and a
number of cardiovascular risk factors, and may have long-
term benefits for patients with metabolic syndrome. These
properties can be attributed to the mode of action of acar-
bose, which directly targets postprandial hyperglycaemia
and avoids several common side-effects associated with
other antidiabetes medications. The most common side-
effects that affect compliance with acarbose therapy are
mild-to-moderate GI events, and these can be minimised
if appropriate stepwise-dosing regimens are used at the
start of treatment. However, acarbose has an excellent
safety profile. Acarbose is therefore a valuable option for
the management of type 2 diabetes and, as the only oral
antidiabetes agent approved for the treatment of predia-
betes, can help to improve clinical management across the
dysglycaemic disease continuum.
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